Medical Xpress
FEBRUARY 3, 2023
Patients can experience 30% fewer serious adverse reactions if their drugs are tailored to their genes, reports a study published in The Lancet. A European collaboration involving researchers from Karolinska Institutet suggests that a genetic analysis prior to drug therapy could significantly reduce suffering and health care costs.
Pharmaceutical Technology
MAY 22, 2023
Thermo Fisher Scientific has expanded its sterile manufacturing and research capabilities in the Asia-Pacific region with the opening of a new sterile drug facility in Singapore. The new good manufacturing practices facility was established with support from the Singapore Economic Development Board.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 5, 2022
The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.
FDA Law Blog
MARCH 13, 2023
Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). By Larry J.
The Pharma Data
OCTOBER 27, 2020
Food and Drug Administration (FDA). Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY ® System. SAN DIEGO , Oct. “To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. .” About Agena Bioscience.
XTalks
DECEMBER 1, 2020
Over the past several years, personalized medicine has led the charge in medical innovation, leading drug development efforts as well as furthering the research community’s understanding of human disease states.
XTalks
JULY 29, 2024
Orphan drug development poses many challenges that are unique to rare diseases, including recruitment in small patient populations, variable progression with heterogenous clinical manifestations and limited understanding of disease progression and natural history. Read on to learn key lessons in rare disease drug development.
Expert insights. Personalized for you.
97 
Let's personalize your content